Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo Company has signed a master agreement for an alliance with The Kitasato Institute for research, development, manufacturing and marketing of human vaccines for the prevention and treatment of infectious diseases in Japan.
Subscribe to our email newsletter
Daiichi Sankyo and The Kitasato Institute’s Research Organization for Infection Control Sciences will discover and develop vaccine seeds together and proactively obtain licenses and technologies from third parties to respond to unmet medical needs of the market by providing highly safe and effective vaccines.
Daiichi Sankyo has shown interest in The Kitasato Institute and its next generation recombinant vaccine technology that uses the internationally-respected AIK-C strain measles vaccine as a vector.